Wayne W Grody

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint ACMG position statement on prenatal/preconception expanded carrier screening
    Wayne W Grody
    Division of Medical Genetics, UCLA School of Medicine, Los Angeles, California, USA
    Genet Med 15:482-3. 2013
  2. ncbi request reprint The Cystic Fibrosis mutation "arms race": when less is more
    Wayne W Grody
    Department of Pathology and Laboratory Medicine, UCLA School of Medicine, Los Angeles, California 90095 1732, USA
    Genet Med 9:739-44. 2007
  3. doi request reprint New quality assurance standards for rare disease testing
    Wayne W Grody
    Department of Pathology and Laboratory Medicine, UCLA School of Medicine, Los Angeles, California 90095 1732, USA
    Genet Med 10:320-4. 2008
  4. pmc Quest for controls in molecular genetics
    Wayne W Grody
    Departments of Pathology and Laboratory Medicine, Pediatrics, and Human Genetics, UCLA School of Medicine, Los Angeles, California 90095 1732, USA
    J Mol Diagn 5:209-11. 2003
  5. pmc Cystic fibrosis testing comes of age
    Wayne W Grody
    Dept of Pathology and Laboratory Medicine, UCLA School of Medicine, 10833 Le Conte Ave, Los Angeles, CA 90095 1732
    J Mol Diagn 11:173-5. 2009
  6. ncbi request reprint Ethical issues raised by genetic testing with oligonucleotide microarrays
    Wayne W Grody
    Divisions of Medical Genetics and Molecular Pathology, Departments of Pathology and Laboratory Medicine, Pediatrics, and Human Genetics, UCLA School of Medicine, Los Angeles, CA, USA
    Mol Biotechnol 23:127-38. 2003
  7. ncbi request reprint Molecular genetic risk screening
    Wayne W Grody
    Department of Pathology, UCLA School of Medicine, Los Angeles, California 90095 1732, USA
    Annu Rev Med 54:473-90. 2003
  8. ncbi request reprint Increased plasma and tissue guanidino compounds in a mouse model of hyperargininemia
    Joshua L Deignan
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA
    Mol Genet Metab 93:172-8. 2008
  9. ncbi request reprint Polyamine homeostasis in arginase knockout mice
    Joshua L Deignan
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1732, USA
    Am J Physiol Cell Physiol 293:C1296-301. 2007
  10. doi request reprint DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study
    Glenn E Palomaki
    Division of Medical Screening and Special Testing, Department of Pathology and Laboratory Medicine, Women and Infants Hospital, Alpert Medical School of Brown University, Providence, Rhode Island, USA
    Genet Med 14:296-305. 2012

Collaborators

Detail Information

Publications58

  1. doi request reprint ACMG position statement on prenatal/preconception expanded carrier screening
    Wayne W Grody
    Division of Medical Genetics, UCLA School of Medicine, Los Angeles, California, USA
    Genet Med 15:482-3. 2013
    ..Patients also must be made aware of the concept of residual risk following negative test results. Laboratories have a duty to participate in and facilitate this information transfer...
  2. ncbi request reprint The Cystic Fibrosis mutation "arms race": when less is more
    Wayne W Grody
    Department of Pathology and Laboratory Medicine, UCLA School of Medicine, Los Angeles, California 90095 1732, USA
    Genet Med 9:739-44. 2007
  3. doi request reprint New quality assurance standards for rare disease testing
    Wayne W Grody
    Department of Pathology and Laboratory Medicine, UCLA School of Medicine, Los Angeles, California 90095 1732, USA
    Genet Med 10:320-4. 2008
  4. pmc Quest for controls in molecular genetics
    Wayne W Grody
    Departments of Pathology and Laboratory Medicine, Pediatrics, and Human Genetics, UCLA School of Medicine, Los Angeles, California 90095 1732, USA
    J Mol Diagn 5:209-11. 2003
  5. pmc Cystic fibrosis testing comes of age
    Wayne W Grody
    Dept of Pathology and Laboratory Medicine, UCLA School of Medicine, 10833 Le Conte Ave, Los Angeles, CA 90095 1732
    J Mol Diagn 11:173-5. 2009
    ..This commentary summarizes the current state of the art of cystic fibrosis genetic testing, highlighting three articles on various aspectives of molecular genetic testing for the CFTR gene (J Mol Diagn 11: 186-193, 211-215, 253-256)...
  6. ncbi request reprint Ethical issues raised by genetic testing with oligonucleotide microarrays
    Wayne W Grody
    Divisions of Medical Genetics and Molecular Pathology, Departments of Pathology and Laboratory Medicine, Pediatrics, and Human Genetics, UCLA School of Medicine, Los Angeles, CA, USA
    Mol Biotechnol 23:127-38. 2003
    ....
  7. ncbi request reprint Molecular genetic risk screening
    Wayne W Grody
    Department of Pathology, UCLA School of Medicine, Los Angeles, California 90095 1732, USA
    Annu Rev Med 54:473-90. 2003
    ..This chapter reviews the basic criteria to be considered before embarking on population genetic risk screening, and examines multiple disease-screening examples representing a variety of modes of inheritance and technical challenges...
  8. ncbi request reprint Increased plasma and tissue guanidino compounds in a mouse model of hyperargininemia
    Joshua L Deignan
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA
    Mol Genet Metab 93:172-8. 2008
    ....
  9. ncbi request reprint Polyamine homeostasis in arginase knockout mice
    Joshua L Deignan
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1732, USA
    Am J Physiol Cell Physiol 293:C1296-301. 2007
    ..These results suggest that endogenous arginase-derived ornithine may not directly contribute to polyamine homeostasis in mice. Alternate sources such as diet may provide sufficient polyamines for maintenance in mammalian tissues...
  10. doi request reprint DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study
    Glenn E Palomaki
    Division of Medical Screening and Special Testing, Department of Pathology and Laboratory Medicine, Women and Infants Hospital, Alpert Medical School of Brown University, Providence, Rhode Island, USA
    Genet Med 14:296-305. 2012
    ..To determine whether maternal plasma cell-free DNA sequencing can effectively identify trisomy 18 and 13...
  11. doi request reprint Disruption of arginase II alters prostate tumor formation in TRAMP mice
    Shannon M Mumenthaler
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1732, USA
    Prostate 68:1561-9. 2008
    ..However, the biological function of arginase II in prostate cancer still remains to be elucidated. In this study, we utilized the TRAMP mouse prostate cancer model to better understand the contribution of AII on tumor development...
  12. pmc A prospective, longitudinal study of the impact of GJB2/GJB6 genetic testing on the beliefs and attitudes of parents of deaf and hard-of-hearing infants
    Christina G S Palmer
    Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA 90095, USA
    Am J Med Genet A 149:1169-82. 2009
    ....
  13. ncbi request reprint Risk calculations for cystic fibrosis in neonatal screening by immunoreactive trypsinogen and CFTR mutation tests
    Shuji Ogino
    Department of Pathology, Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Genet Med 7:317-27. 2005
    ..Although neonatal screening (or newborn screening) for cystic fibrosis (CF) is commonly practiced, systematic methods for accurate risk calculations are currently lacking...
  14. pmc Long-term survival of the juvenile lethal arginase-deficient mouse with AAV gene therapy
    Eun K Lee
    Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 7054, USA
    Mol Ther 20:1844-51. 2012
    ..These studies are the first to demonstrate that AAV-based therapy for arginase deficiency is effective and supports the development of gene therapy for this and the other urea cycle disorders...
  15. ncbi request reprint Testing and reporting ACMG cystic fibrosis mutation panel results
    Roger V Lebo
    Department of Pathology, Akron Children s Hospital, Akron, OH 44308 1062, USA
    Genet Test 11:11-31. 2007
    ..These tables posterior test risks also indicate that when one partner with no family history tests negative for the 23 mutation panel, no further prenatal testing is indicated...
  16. doi request reprint An exon 1 deletion in OTC identified using chromosomal microarray analysis in a mother and her two affected deceased newborns: implications for the prenatal diagnosis of ornithine transcarbamylase deficiency
    Fabiola Quintero-Rivera
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Mol Genet Metab 101:413-6. 2010
    ....
  17. pmc Contrasting features of urea cycle disorders in human patients and knockout mouse models
    Joshua L Deignan
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, CA 90095 1732, USA
    Mol Genet Metab 93:7-14. 2008
    ..Consequently, all of the current mouse models are highly useful for future research into novel pharmacological and dietary treatments and gene therapy protocols for the management of urea cycle disorders...
  18. ncbi request reprint Ethnic differences in parental perceptions of genetic testing for deaf infants
    Christina G S Palmer
    Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA 90024, USA
    J Genet Couns 17:129-38. 2008
    ..Understanding different perspectives on genetic testing for deafness will enhance genetic counselors' cultural competence and facilitate the pre-test genetic counseling session...
  19. pmc Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing
    Frank S Ong
    Department of Biomedical Sciences, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Expert Rev Mol Diagn 12:593-602. 2012
    ....
  20. ncbi request reprint Bayesian analysis for cystic fibrosis risks in prenatal and carrier screening
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Genet Med 6:439-49. 2004
    ..Our methods are particularly useful for calculating the CF disease risk for a fetus with echogenic bowel. In genetics practice, however, there are other scenarios for which our previous methods are inadequate...
  21. ncbi request reprint Sharing GJB2/GJB6 genetic test information with family members
    Terri Blase
    Department of Biology, California State University Northridge, Northridge, CA, USA
    J Genet Couns 16:313-24. 2007
    ..Differences suggest that hearing loss may have unique attributes that influence responses to genetic test information. Further research is needed to replicate these findings...
  22. ncbi request reprint Expression of arginase II in prostate cancer
    Shannon M Mumenthaler
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, 650 Charles E Young Drive South, Los Angeles, CA 90095 1732, USA
    Int J Oncol 32:357-65. 2008
    ..More specifically, the elevated AII expression seen in androgen-dependent and in more differentiated prostate cancers suggests that AII could be a potentially useful marker of early stage prostate adenocarcinoma...
  23. pmc Short-term correction of arginase deficiency in a neonatal murine model with a helper-dependent adenoviral vector
    Chia Ling Gau
    Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Mol Ther 17:1155-63. 2009
    ..These studies demonstrate that the AI deficient newborn mouse can be temporarily corrected and rescued using a HDV...
  24. doi request reprint Ordering genetic tests and interpreting the results
    Joshua L Deignan
    University of California Los Angeles, Los Angeles, Calif, USA
    Adv Otorhinolaryngol 70:18-24. 2011
    ....
  25. ncbi request reprint Microelectronic array system for molecular diagnostic genotyping: Nanogen NanoChip 400 and molecular biology workstation
    Dianne Keen-Kim
    University of California Los Angeles, Center for Neurobehavioral Genetics, 965 Charles E Young Dr South, Gonda 3554, Los Angeles, CA 90095, USA
    Expert Rev Mol Diagn 6:287-94. 2006
    ..It is beyond the scope of this review to describe the use of NanoChip platforms in basic research, and to compare it against all available clinical single nucleotide polymorphism genotyping applications and platforms...
  26. ncbi request reprint Arginase expression in mouse embryonic development
    Hong Yu
    Mental Retardation Research Center, UCLA, 760 Westwood Plaza, Los Angeles, CA 90024 1759, USA
    Mech Dev 115:151-5. 2002
    ..The strong AI expression in the peripheral nervous system suggests that the pathogenesis of the neurological retardation in AI deficiency may be conditioned by AI deficiency in the nervous system during embryonic development...
  27. pmc Lethal phenotype in conditional late-onset arginase 1 deficiency in the mouse
    Jennifer Kasten
    Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Mol Genet Metab 110:222-30. 2013
    ....
  28. ncbi request reprint Variable penetrance and expressivity of the splice altering 5T sequence in the cystic fibrosis gene
    Roger V Lebo
    Department of Pathology, Akron Children s Hospital, Akron, OH 44308 1062, USA
    Genet Test 11:32-44. 2007
    ....
  29. pmc A novel method for creating artificial mutant samples for performance evaluation and quality control in clinical molecular genetics
    Michael Jarvis
    Department of Pathology and Laboratory Medicine, University of California at Los Angeles School of Medicine, 10833 Le Conte Ave, Los Angeles, CA 90095 1732, USA
    J Mol Diagn 7:247-51. 2005
    ....
  30. ncbi request reprint Cloning and characterization of human agmatinase
    Ramaswamy K Iyer
    Department of Pathology and Laboratory Medicine, UCLA School of Medicine, Los Angeles, California 90095 1732, USA
    Mol Genet Metab 75:209-18. 2002
    ..It has 56% similarity to E. coli agmatinase and 42% similarity to human arginases I and II and shares highly conserved substrate-binding domains with these well-characterized enzymes...
  31. pmc Mouse model for human arginase deficiency
    Ramaswamy K Iyer
    Department of Pathology and Laboratory Medicine and the Mental Retardation Research Center, University of California Los Angeles School of Medicine, Los Angeles, California 90095 1732, USA
    Mol Cell Biol 22:4491-8. 2002
    ....
  32. pmc Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia
    Sheeja T Pullarkat
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, CHS, A7 149, Los Angeles, CA, 90095 1732, USA
    J Hematop 2:27-33. 2009
    ..SM associated with t(8;21) AML carries a dismal prognosis; therefore, detection of concurrent SM at diagnosis of t(8;21) AML has important prognostic implications...
  33. pmc Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation
    Frank S Ong
    Department of Biomedical Sciences, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Pharmacogenomics 13:465-75. 2012
    ..We also discuss the effect of HMGCR/LDLR in decreasing the effectiveness of low-density lipoprotein cholesterol with statin therapy, the SLCO1B1 genotype and simvastatin myotoxicity, and ADRB1/ADD1 for antihypertensive response...
  34. pmc Arginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy
    Michelle Wehling-Henricks
    Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, California, USA
    PLoS ONE 5:e10763. 2010
    ....
  35. ncbi request reprint Expression of the liver form of arginase in erythrocytes
    Phillip S Kim
    Department of Pathology and Laboratory Medicine, University of California at Los Angeles School of Medicine, 10833 Le Conte Avenue, 90095 1732, USA
    Mol Genet Metab 76:100-10. 2002
    ....
  36. ncbi request reprint Widespread expression of arginase I in mouse tissues. Biochemical and physiological implications
    Hong Yu
    Mental Retardation Research Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1732, USA
    J Histochem Cytochem 51:1151-60. 2003
    ....
  37. ncbi request reprint Arginases I and II: do their functions overlap?
    Stephen D Cederbaum
    Department of Psychiatry, David Geffen School of Medicine at the University of California, Los Angeles, USA
    Mol Genet Metab 81:S38-44. 2004
    ..Finally, prenatal diagnosis appears to be possible as was predicted, but never proven, some years ago...
  38. doi request reprint DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study
    Glenn E Palomaki
    Division of Medical Screening and Special Testing, Department of Pathology and Laboratory Medicine, Women and Infants Hospital, Alpert Medical School of Brown University, Providence, Rhode Island 02903, USA
    Genet Med 13:913-20. 2011
    ..Prenatal screening for Down syndrome has improved, but the number of resulting invasive diagnostic procedures remains problematic. Measurement of circulating cell-free DNA in maternal plasma might offer improvement...
  39. doi request reprint Stuck between a scalpel and a rock, or molecular pathology and legal-ethical issues in use of tissues for clinical care and research: what must a pathologist know?
    Sarah Dry
    Department of Pathology and Laboratory Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA
    Am J Clin Pathol 137:346-55. 2012
    ..This article reviews these rapidly evolving and complex areas...
  40. ncbi request reprint Should we be applying warfarin pharmacogenetics to clinical practice? No, not now
    Michael H Rosove
    University of California, Los Angeles, Los Angeles, California 90095, USA
    Ann Intern Med 151:270-3, W95. 2009
    ..Further study is required before routine warfarin pharmacogenetic testing can be recommended...
  41. ncbi request reprint Ornithine deficiency in the arginase double knockout mouse
    Joshua L Deignan
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Mol Genet Metab 89:87-96. 2006
    ..Although most human AI-deficient patients have no symptomatic hyperammonemia at birth, it is possible that clinically significant ornithine deficiency is already present...
  42. pmc Keeping up with the next generation: massively parallel sequencing in clinical diagnostics
    John R ten Bosch
    Departments of Human Genetics, University of California at Los Angeles School of Medicine, Los Angeles, California, USA
    J Mol Diagn 10:484-92. 2008
    ..In this review, technical issues are discussed, in addition to the practical considerations that will need to be addressed as advances push toward personal genome sequencing...
  43. ncbi request reprint Prelingual siblings of children with GJB2 hearing loss: issues to consider
    Christina G S Palmer
    Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, UCLA Neuropsychiatric Institute, 90095, USA
    Arch Otolaryngol Head Neck Surg 131:1020-2. 2005
  44. pmc An electrochemical detection scheme for identification of single nucleotide polymorphisms using hairpin-forming probes
    Tony Jun Huang
    Mechanical and Aerospace Engineering Department, University of California Los Angeles, Los Angeles, CA 90095 1597, USA
    Nucleic Acids Res 30:e55. 2002
    ..We have demonstrated that the system successfully identified the factor V Leiden mutations from human blood specimens...
  45. ncbi request reprint Discordant pursuit asymmetry and esotropia in monozygous twins
    Pradeep Sharma
    Department of Ophthalmology, University of California, Los Angeles, USA
    Am J Ophthalmol 134:143-6. 2002
    ..To report the relationship between infantile esotropia and asymmetry of monocular pursuit tracking...
  46. ncbi request reprint Cystic fibrosis mutations in Costa Rica
    Patricia B Venegas
    Laboratorio de Genetica, Hospital Nacional de Ninos, San Jose, Costa Rica
    Hum Biol 75:179-88. 2003
    ....
  47. ncbi request reprint Developing a sustainable process to provide quality control materials for genetic testing
    Bin Chen
    Quality Control Materials for Genetic Testing Group, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA
    Genet Med 7:534-49. 2005
    ....
  48. ncbi request reprint Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G >A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories
    Elaine B Spector
    Factor V Leiden Working Group, University of Colorado School of Medicine, CO, USA
    Genet Med 7:444-53. 2005
    ..It may be prudent, however, to document in the laboratory record the rationale for any significant deviation from these standards and guidelines...
  49. ncbi request reprint Genetic testing as part of the early hearing detection and intervention (EHDI) process
    Lisa A Schimmenti
    Department of Pediatrics and Institute of Human Genetics, University of Minnesota, USA
    Genet Med 6:521-5. 2004
  50. ncbi request reprint Cystic fibrosis carrier screening: issues in implementation
    Michael S Watson
    Genet Med 4:407-9. 2002
  51. ncbi request reprint Standards and guidelines for CFTR mutation testing
    Carolyn Sue Richards
    Molecular Subcommittee of the Laboratory Quality Assurance Committee, American College of Medical Genetics, 9650 Rockville Pike, Bethesda, MD 20914 3998, USA
    Genet Med 4:379-91. 2002
    ..We take the view that these technologies will change, and thus this document will change with future review...
  52. pmc Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel
    Michael S Watson
    ACMG Cystic Fibrosis Carrier Screening Work Group, American College of Medical Genetics, Bethesda, Maryland 20814, USA
    Genet Med 6:387-91. 2004
  53. ncbi request reprint Prenatal screening for cystic fibrosis: past, present and future
    Carolyn S Richards
    Department of Molecular and Medical Genetics, DNA Diagnostic Laboratory, Oregon Health Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Expert Rev Mol Diagn 4:49-62. 2004
    ..An even greater challenge is clinical implementation, which focuses upon education and communication, choosing models, reporting, counseling and prenatal diagnosis...
  54. ncbi request reprint Alternative approaches to proficiency testing in molecular genetics
    C Sue Richards
    Clin Chem 49:717-8. 2003
  55. doi request reprint Infant hearing loss and connexin testing in a diverse population
    Lisa A Schimmenti
    Department of Pediatrics, Institute of Human Genetics, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    Genet Med 10:517-24. 2008
    ..This is the first study to differentiate infants with and without connexin-related hearing loss...
  56. ncbi request reprint Cystic fibrosis mutation analysis: how many is enough?
    Gregory J Tsongalis
    Genet Med 6:456-8. 2004
  57. ncbi request reprint Monitoring standards for molecular genetic testing in the United Kingdom, the Netherlands, and Ireland
    Simon C Ramsden
    National Genetics Reference Laboratory Manchester, St Mary s Hospital, Manchester, UK
    Genet Test 10:147-56. 2006
    ....
  58. ncbi request reprint Estimated analytic validity of HFE C282Y mutation testing in population screening: the potential value of confirmatory testing
    Glenn E Palomaki
    Foundation for Blood Research, Scarborough, Maine 04070 0190, USA
    Genet Med 5:440-3. 2003
    ..The purpose of this study was to estimate analytic sensitivity and specificity of HFE testing for C282Y homozygosity in the hypothetical setting of population screening for hemochromatosis...